{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T22:40:06Z","timestamp":1782772806438,"version":"3.54.5"},"reference-count":47,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Introduction: Peritoneal metastasis (PM) is the most common site of recurrence following curative resection for advanced gastric cancer (GC). Along with disease progression, it can lead to complications such as intestinal obstruction, hydronephrosis, obstructive jaundice, and ascites, significantly impairing the patient\u2019s quality of life. Therefore, peritoneal metastasis is considered a critical target for treatment. In general, these patients are treated with systemic chemotherapy; however, the therapeutic effect is often limited due to the anticancer agents\u2019 poor penetration into the peritoneal cavity. We aim to identify factors associated with the best overall survival (OS) in GC patients with peritoneal metastasis. Methods: Patients with advanced GC who were diagnosed as having macroscopic PM or positive peritoneal cytology by staging laparoscopy were enrolled. We introduced intraperitoneal Paclitaxel (IP-PTX) combined with S-1 plus oxaliplatin (SOX). Gastrectomy with lymph node dissection was performed as conversion surgery when the PM showed an excellent response. Results: Ninety-six patients received IP-PTX + SOX, with a median of 16 courses. The 1- and 5-year OS rates were 70.2% and 24.5%, respectively, with a mean survival time (MST) of 20.0 months. No chemotherapy-related mortality was observed. Conversion surgery was performed in 44 patients (45.8%), with a 1-year OS rate of 100%. Conclusions: Combination chemotherapy using the IP-PTX + SOX regimen is highly effective and is recommended as induction chemotherapy for patients with PM from GC. Conversion gastrectomy should be considered following an excellent response, particularly in patients with peritoneal cancer index (PCI) scores below 20.<\/jats:p>","DOI":"10.3390\/jcm14103521","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T06:31:29Z","timestamp":1747636289000},"page":"3521","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in Intraperitoneal Chemotherapy for Gastric Cancer Patients with Peritoneal Metastases: Current Status of Treatment and Institutional Insights"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2931-4260","authenticated-orcid":false,"given":"Shin","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Surgery, Jichi Medical University, Saitama 330-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-9410","authenticated-orcid":false,"given":"Hironori","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Surgery, Jichi Medical University, Saitama 330-8503, Japan"},{"name":"Division of Clinical Oncology, Jichi Medical University, Saitama 330-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Jichi Medical University, Saitama 330-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Surgery, Jichi Medical University, Saitama 330-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-2840","authenticated-orcid":false,"given":"Hideyuki","family":"Ohzawa","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology, Jichi Medical University, Saitama 330-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8809-443X","authenticated-orcid":false,"given":"Shinichiro","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Surgery, Jichi Medical University, Saitama 330-8503, Japan"},{"name":"Division of Abdominal Transplant, Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-7130","authenticated-orcid":false,"given":"Joji","family":"Kitayama","sequence":"additional","affiliation":[{"name":"Department of Surgery, Jichi Medical University, Saitama 330-8503, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Jemal A: Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/jso.26894","article-title":"Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease","volume":"125","author":"Khan","year":"2022","journal-title":"J. Surg. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.12998\/wjcc.v7.i20.3247","article-title":"Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis: A systemic review and meta-analysis","volume":"7","author":"Zheng","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"569","DOI":"10.4251\/wjgo.v12.i5.569","article-title":"Gastric cancer with peritoneal metastases: Efficiency of standard treatment methods","volume":"12","author":"Yarema","year":"2020","journal-title":"World J. Gastrointest. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejso.2013.10.019","article-title":"Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials","volume":"40","author":"Coccolini","year":"2014","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.3748\/wjg.v22.i33.7478","article-title":"Regional but fatal: Intraperitoneal metastasis in gastric cancer","volume":"22","author":"Wei","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1007\/s00595-020-02222-0","article-title":"Current status of conversion surgery for stage IV gastric cancer","volume":"51","author":"Kinoshita","year":"2021","journal-title":"Surg. Today"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/1055-9965.EPI-13-1057","article-title":"Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention","volume":"23","author":"Karimi","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1046\/j.1365-2168.2000.01360.x","article-title":"Recurrence following curative resection for gastric carcinoma","volume":"87","author":"Yoo","year":"2000","journal-title":"Br. J. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11605-016-3336-3","article-title":"Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?","volume":"21","author":"Chan","year":"2017","journal-title":"J. Gastrointest. Surg."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.21.02745","article-title":"Integration of Genomic Biology into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis","volume":"40","author":"Gwee","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1111\/jcmm.17922","article-title":"Gastric cancer peritoneal metastasis related signature predicts prognosis and sensitivity to immunotherapy in gastric cancer","volume":"27","author":"Sun","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12957-020-01813-y","article-title":"Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma","volume":"18","author":"Allen","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","article-title":"S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial","volume":"9","author":"Koizumi","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10120-014-0417-4","article-title":"Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer","volume":"18","author":"Saito","year":"2015","journal-title":"Gastric Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e000031","DOI":"10.1136\/esmoopen-2015-000031","article-title":"Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: Correlative study in the JCOG9912 phase III trial","volume":"1","author":"Kurokawa","year":"2016","journal-title":"ESMO Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/annonc\/mdp260","article-title":"Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis","volume":"21","author":"Ishigami","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","article-title":"Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G)","volume":"23","author":"Nakajima","year":"2020","journal-title":"Gastric Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: The randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): A multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21037\/jgo-24-743","article-title":"Expression of Claudin18.2 in metastatic lesions in peritoneum of gastric cancer","volume":"16","author":"Saito","year":"2025","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s10120-024-01535-0","article-title":"Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial","volume":"27","author":"Boku","year":"2024","journal-title":"Gastric Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","article-title":"Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases","volume":"28","author":"Saito","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOE-NIX-GC Trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1111\/j.1349-7006.2009.01265.x","article-title":"Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer","volume":"100","author":"Soma","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2147\/CMAR.S343467","article-title":"Prediction of Peritoneal Cancer Index and Prognosis in Peritoneal Metastasis of Gastric Cancer Using NLR-PLR-DDI Score: A Retrospective Study","volume":"14","author":"Ye","year":"2022","journal-title":"Cancer Manag. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1515\/pp-2017-0004","article-title":"Modelling drug transport during intraperitoneal chemotherapy","volume":"2","author":"Steuperaert","year":"2017","journal-title":"Pleura Peritoneum"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4613-1247-5_4","article-title":"Peritoneal-plasma barrier","volume":"82","author":"Jacquet","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm.2017.125","article-title":"Shedding light on the cell biology of extracellular vesicles","volume":"19","author":"Raposo","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_35","first-page":"228","article-title":"microRNA-21 stimulates gastric cancer growth and invasion by inhibiting the tumor suppressor effects of programmed cell death protein 4 and phosphatase and tensin homolog","volume":"19","author":"Li","year":"2014","journal-title":"J. BUON"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1158\/1541-7786.MCR-10-0529","article-title":"miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3","volume":"9","author":"Li","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1245\/s10434-020-09007-2","article-title":"Ratios of miRNAs in Peritoneal Exosomes are Useful Biomarkers to Predict Tumor Response to Intraperitoneal Chemotherapy in Patients with Peritoneal Metastases from Gastric Cancer","volume":"27","author":"Ohzawa","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_38","first-page":"539","article-title":"The role of miR-29b in cancer: Regulation, function, and signaling","volume":"8","author":"Yan","year":"2015","journal-title":"Onco Targets Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.omto.2018.12.011","article-title":"A systematic review of miR-29 in cancer","volume":"12","author":"Kwon","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41417-024-00837-w","article-title":"Kitayama: Intraperitoneal administration of adeno-associated virus encoding microRNA-29b for the treatment of peritoneal metastasis","volume":"31","author":"Kaneko","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10120-017-0726-5","article-title":"Importance of human peritoneal mesothelial cells in the progression, fibrosis, and control of gastric cancer: Inhibition of growth and fibrosis by tranilast","volume":"21","author":"Saito","year":"2018","journal-title":"Gastric Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/path.4695","article-title":"Mesothelial-to-mesenchymal transition in the pathogenesis of post-surgical peritoneal adhesions","volume":"239","author":"Sandoval","year":"2016","journal-title":"J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Kojima, M., Higuchi, Y., Yokota, M., Ishii, G., Saito, N., Aoyagi, K., Sasaki, H., and Ochiai, A. (2014). Human subperitoneal fibroblast and cancer cell interaction creates microenvironment that enhances tumor progression and metastasis. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088018"},{"key":"ref_44","first-page":"6991","article-title":"Mechanisms of peritoneal dissemination in gastric cancer","volume":"14","author":"Sun","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/ijc.32854","article-title":"Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1\/Akt signaling pathway","volume":"146","author":"Yoshihara","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"19280","DOI":"10.1002\/jcp.28607","article-title":"The potential role of miR-29 in health and cancer diagnosis, prognosis, and therapy","volume":"234","author":"Alizadeh","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/cas.15793","article-title":"Intraperitoneal transfer of microRNA-29b-containing small extracellular vesicles can suppress peritoneal metastases of gastric cancer","volume":"114","author":"Kimura","year":"2023","journal-title":"Cancer Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3521\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:34:33Z","timestamp":1760031273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/10\/3521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,17]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["jcm14103521"],"URL":"https:\/\/doi.org\/10.3390\/jcm14103521","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,17]]}}}